Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Expense - Debt (2021 - 2022)

Historic Interest Expense - Debt for Guided Therapeutics (GTHP) over the last 2 years, with Q2 2022 value amounting to -$11503.0.

  • Guided Therapeutics' Interest Expense - Debt fell 20000.0% to -$11503.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $28094.0, marking a year-over-year change of. This contributed to the annual value of $39597.0 for FY2022, which is 0.0% changed from last year.
  • According to the latest figures from Q2 2022, Guided Therapeutics' Interest Expense - Debt is -$11503.0, which was down 20000.0% from $39597.0 recorded in Q1 2022.
  • Guided Therapeutics' Interest Expense - Debt's 5-year high stood at $39597.0 during Q1 2022, with a 5-year trough of -$11503.0 in Q2 2022.